Polypill research shows potential to reduce heart attack and stroke risks

Researchers are investigating the efficacy and eligibility of a polypill—a single tablet combining multiple medications—to prevent major cardiovascular events such as heart attacks and strokes.

A study conducted by Tehran University of Medical Sciences involving approximately 6,800 adults in Iran found that the polypill, which contains low-dose aspirin, atorvastatin, hydrochlorothiazide, and enalapril, reduced the risk of major cardiovascular events by about one-third compared to usual care. In the study, 6% of the polypill group experienced major events, while 9% of the usual-care group did so over five years.

Additional research involving Weill Cornell Medical College and GHESKIO has focused on estimating eligibility for polypill use for atherosclerotic cardiovascular disease prevention in low-income settings like Haiti.